Business Context and Reporting Period
This Form 8-K is a current report filed by Eastman Chemical Company on March 10, 2025. The filing addresses Item 5.02 regarding the departure of directors or certain officers and compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation terms rather than financial performance.
Material Changes
On March 10, 2025, the Company entered into a severance agreement with Brad A. Lich. This agreement establishes eligibility for severance benefits contingent upon specific termination events and compliance with restrictive covenants.
Guidance, Outlook, and Management Commentary
The filing details the terms of the severance agreement for Mr. Lich:
- Triggering Events: Termination without "Cause" or resignation for "good reason" after March 1, 2027.
- Cash Severance: A payment of $2 million plus any additional amounts eligible under existing company severance plans.
- Healthcare: Up to four months of continued healthcare coverage paid by the Company.
- Conditions: Benefits are contingent on Mr. Lich providing a general release of claims and not revoking it.
The full text of the agreement will be filed as an exhibit to the Company's Form 10-Q for the first quarter of 2025.
Investor Verification Checklist
- Verify the definition of "Cause" and "good reason" in the Company's 2021 Omnibus Stock Compensation Plan and the specific Agreement.
- Confirm the total potential liability by reviewing existing severance plans that may supplement the $2 million base payment.
- Monitor the upcoming Form 10-Q for Q1 2025 to review the full text of the severance agreement.
- Assess the impact of this agreement on future executive compensation expenses if a qualifying termination occurs.